Blog
01/01/2025
The Year in Review: 5 Small-Molecule Drugs Approved by the FDA in 2024
Since January 2024, 46 novel drugs have been approved by the U.S. Food and Drug Administration (FDA), with roughly half of these being small molecules. These innovations represent life-saving progress in the treatment of a wide range of human diseases, […]
12/03/2024
ICP-MS: Biomedical Advances and Experimental Applications
Inductively coupled plasma mass spectrometry (ICP-MS) is a powerful technique for the trace and ultra-trace elemental analysis of a variety of sample types. As the name indicates, this technology makes use of a high-energy argon plasma to break down nebulized […]
10/24/2024
Mass Spectrometry & Proteomics for Covalent Lead Discovery
Covalent drugs and degraders, defined by their ability to form covalent bonds with their targets, represent a powerful therapeutic modality for the potent and selective inhibition, modulation, or degradation of clinically relevant proteins. Thanks to technological innovations facilitating the screening […]
08/30/2024
TPD/PROTAC as a transformative drug discovery paradigm
Traditional drug development depends upon the discovery of a small molecule that binds to the active site of a protein of interest (POI) and functionally blocks its activity. However, this type of ‘occupancy-driven’ pharmacology is only suitable for a narrow […]
08/09/2024
The DELephant in the Room
DNA-encoded libraries – DELs, for short – have attracted the attention of the pharmaceutical industry in recent years, promising the ability to readily screen millions or billions of potential ligands in parallel by linking small-molecule test compounds to unique DNA […]
07/17/2024
Screening Strategies for RNA-Targeted Small-Molecule Drugs
The ability to target RNA with small-molecule drugs presents a powerful opportunity for therapeutic intervention. In contrast to traditional drugs, which generally act against proteins, these drugs interact with RNA molecules. In most cases, they function by modulating splicing or […]
05/01/2023
Intact Mass Screening for Covalent Compound Libraries: What and Why?
Recent publications highlight an “evolving toolbox” of techniques and technologies implemented in covalent inhibitor discovery and design. Though historically covalent compound discovery has been conducted via structure based drug design, direct covalent ligand screening of electrophilic compound libraries has been […]
02/24/2023
Affinity Selection Mass Spectrometry (ASMS): What and Why?
Affinity Selection Mass Spectrometry (ASMS) is a high throughput screening (HTS) technique for identifying small molecule test compounds based on their binding affinity to a target. Unlike traditional biochemical assays that test a compound’s functional activity, ASMS is a biophysical […]